TPN-101 Webinar

THIS IS IN DRAFT

Webinar Outline

Introduction (5 minutes):

To be presented by the AGSAA

  • Welcome and introductions

  • Importance of clinical trials for the development of new medicines

  • Brief introduction and handoff for Andy and Transposon

Transposon overview (10 minutes):

To be presented by Transponson’s Medical Director

  • Overview of Transposon's history and mission

  • Explanation of their new medicine and how it works

  • Brief summary of the preclinical research that led to the clinical trial

  • Explanation of available safety data, including any preclinical safety studies and early-phase clinical trials that have been conducted to assess the safety and tolerability of the medicine

  • Highlight any compensation or incentives that will be provided

  • Share Transposon’s plan to keep families informed of trial developments

Trial procedures (15 minutes):

To be presented by Site Investigators.

  • Introduction of the site investigators (AGS doctors) who will explain the trial procedures

  • Overview of the inclusion and exclusion criteria for the trial

  • Discussion of the trial design, including the number of participants and the length of the trial

  • Detailed explanation of the trial procedures by the site investigators, including the medication dosage and frequency, the study visits, and any tests or assessments that will be performed

  • Discussion of the potential risks and benefits of participating in the trial from the clinician’s perspective

Conclusion (5 minutes):

To be presented by the AGSAA

  • Recap of key points

  • Q&A session to address any remaining questions or concerns

  • Information about how to contact Transposon or the site investigators for further information or to participate in the trial

  • Highlight AGS patient registry and AGSAA contact list as ways to stay up to date